To explore the value of spectral CT in the diagnosis and treatment of liver cancer
To explore the value of spectral CT in the diagnosis and treatment of liver cancer: The CT scan is part of the standard treatment protocol.
Study summary
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
2. Age \> 18 years.
3. Patients suspected of having liver cancer.
4. Patients who have signed the informed consent form.
Exclusion Criteria:
1. Severe cardiac, pulmonary, or renal insufficiency.
2. Allergy to iodine-based contrast agents.
3. Inability to cooperate with the CT examination.
4. Poor image quality of the Quark Spectral CT scan.
5. Women who are pregnant or breastfeeding.
Primary outcome measure(s)
Pathological TNM staging — 1 day Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.